Human Microbiome Market - Industry Size, Share, Growth & Forecast 2028 | UnivDatos

Human microbiome consists of various microorganisms, including archaea, viruses, bacteria, and eukaryotes which reside within or outside the human body. These microorganisms have been shown to have a significant impact on human physiology, and therefore play a critical role in metabolic and immune functions. The global human microbiome market is growing at a high rate which is due to their applications in human health. The major applications of microbiome products include predictive, preventive, and personalized medicine.

The Human Microbiome Market is expected to grow at a steady rate of around 26.7% during the forecast period (2022-2028). In the last decade, microbiome therapy has gained enormous attention from the government as well as private organizations. For instance, from 2007-2016, the National Institute of Health (NIH) invested USD 215 million in the Human Microbiome Project (HMP) and USD 728 million in extramural human microbiome research activities. Apart from this, Horizon 2020 is one of the biggest European Union research and innovation programs which received funding of USD 96.9 million available for seven years (2014-2020).

Unlock The Table of Content, And Request a Sample Report - https://univdatos.com/get-a-free-sample-form-php/?product_id=28343

According to UnivDatos Market Insights (UMI)’ research report “Global Human Microbiome Market”, the market is expected to witness robust growth during the forecast period (2022-2028). The growth of the market is driven by factors such as rising chronic disease due to changes in lifestyle and growing interest in the human microbiome treatment approach. Several key companies are getting funds to fasten the process of development of therapeutic drugs. For instance, in 2022, OptiBiotix Health Plc. signed an exclusive sales and distribution agreement with Nahdi medical Co. to help tackle the obesity epidemic. 

Based on product type, the market is segmented into probiotics, prebiotics, diagnostic tests, drugs, medical foods, supplements, and others. The drugs segment is expected to grow with high CAGR rates during the forecast period which is mainly attributed to the rising number of human microbiome-based therapeutic products in clinical trials along with increased funding to develop microbiome-based medications.

Based on the application, the market is categorized into diagnostics and therapeutics. The therapeutics segment held the dominant share in the global market due to increased funding in research and development for microbiome-based therapies, technological advancements, and an increase in the prevalence of chronic diseases.

Unlock The Table of Content, And Request a Sample Report - https://univdatos.com/get-a-free-sample-form-php/?product_id=28343

Based on the disease, the human microbiome market is segmented into obesity, infectious diseases, cancer, autoimmune diseases, metabolic & gastrointestinal disorders, and others. The infectious disease segment is expected to witness high CAGR rates during the forecast period. The surge in the incidence of infections due to microbial dysbiosis, as a result of antibiotic treatment, and the rising number of clinical trials for the development of target-specific microbiome-based therapies are the major factors propelling the growth of this segment during the forecast period.

Based on the distribution channel, the human microbiome market has been classified into retail pharmacies, hospital pharmacies, and online pharmacies. Online pharmacies are expected to grow with high growth rates which are attributed to the surge in mobile usage, high internet penetration, and an increase in the number of people conducting online transactions that have raised the demand for online drugs through app-based platforms in recent years.

APAC to witness extensive growth

For a better understanding of the market adoption of the human microbiome industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to a rise in government initiatives to enhance awareness, an increase in medical tourism, increasing research and development activities in the region, and a rise in the incidences of chronic diseases, autoimmune disorders, and lifestyle-related disorders. For example, the 5th Microbiome R&D and Business Collaboration Congress were held in Taiwan, Asia in March 2019, the conference focused on recent developments in the gut microbiome, skin microbiome, infant, women and oral health, therapeutics, microbiome, and diet.

For More Informative Information, Please Visit Us – https://univdatos.com/report/human-microbiome-market/

According to UnivDatos Market Insights (UMI)’, the key players with a considerable market share in the human microbiome market are Enterome Biosciences SA, Yakult Honsha Co., 4D Pharma, Second Genome, Seres Therapeutics, Vedanta Biosciences, Inc., AOBiome, Microbiome Therapeutics LLC, and OptiBiotix HEALTH PLC.

“Global Human Microbiome Market” provides comprehensive qualitative and quantitative insights on the industry potential, key factors impacting sales and purchase decisions, hotspots, and opportunities available for the market players. Moreover, the report also encompasses the key strategic imperatives for success for competitors along with strategic factorial indexing measuring competitors’ capabilities on different parameters. This will help companies in the formulation of go-to-market strategies and identifying the blue ocean for its offerings.        

Market Segmentation:

1.      By Product Type (Probiotics, Prebiotics, Diagnostic Tests, Drugs, Medical Foods, Supplements, and Others.)

2.      By Application (Diagnostics and Therapeutics)

3.      By Disease (Obesity, Infectious Diseases, Cancer, Autoimmune Diseases, Metabolic & Gastrointestinal Disorders, and Others)

4.      By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies)

5.      By Region (North America, Europe, Asia-Pacific, Rest of the World)

6.      By Company (Enterome Biosciences SA, Yakult Honsha Co., 4D Pharma, Second Genome, Seres Therapeutics, Vedanta Biosciences, Inc., AOBiome, Microbiome Therapeutics LLC, and OptiBiotix HEALTH PLC.)

Key questions answered in the study:

1.      What are the current and future trends of the global human microbiome industry?

2.      How the industry has been evolving in terms of product type, application, disease, and distribution channel?

3.      How the competition has been shaping across the countries followed by their comparative factorial indexing?

4.      What are the key growth drivers and challenges for the global human microbiome industry?

5.      What is the customer orientation, purchase behavior, and expectations from the global human microbiome suppliers across various region and countries?